lometrexol profile

lometrexol: RN & structure given in first source; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	135413518
CHEMBL ID	34412
SCHEMBL ID	18530
SCHEMBL ID	17520098
MeSH ID	M0133239

Synonym
ly264618
CHEMBL34412
ddathf-b
ly-264618
t-64
bdbm22590
(2s)-2-[(4-{2-[(6r)-2-amino-4-oxo-1h,4h,5h,6h,7h,8h-pyrido[2,3-d]pyrimidin-6-yl]ethyl}phenyl)formamido]pentanedioic acid
lometrexol
ddathf
5,10-dideazatetrahydrofolic acid
(2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid
ly 264618
lometrexol [inn:ban]
6p3avy8a7q ,
106400-81-1
l-glutamic acid, n-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-, (r)-
l-glutamic acid, n-(4-(2-((6r)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-
lometrexolum [inn-latin]
lometrexolum
unii-6p3avy8a7q
lometrexol [inn]
l-glutamic acid, n-(4-(2-(2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-, (r)-
lometrexol [who-dd]
n-(p-(2-((r)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-l-glutamate
CCG-222045
SCHEMBL18530
SCHEMBL17520098
NCGC00485206-01
lometrexol(ly 264618)
l-glutamic acid, n-[4-[2-[(6r)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-
DB12769
n-[(4-{2-[(6r)-2-amino-4-oxo-1,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl}phenyl)carbonyl]-l-glutamic acid
NCGC00485206-02
HY-14521
CS-0003423
(4-(2-((r)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl)ethyl)benzoyl)-l-glutamic acid
Q27265261
(2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-3h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid
MS-27983
n-{4-[2-(4-hydroxy-2-imino-1,2,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl}glutamic acid
DTXSID50909998
AKOS040741996

Excerpt	Reference
" Thus, DDATHF did not inhibit the growth of IGROV1 cells depleted of folic acid after stripping FBP with phosphatidylinositol-phospholipase C, even at a dose toxic for cells constitutively expressing FBP."	( Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro. Bottero, F; Canevari, S; D'Incalci, M; Erba, E; Sen, S; Tomassetti, A, 1996)

Excerpt	Reference
" No marked differences were evident in lometrexol plasma half-lives, plasma clearance, or the extent of plasma protein binding, indicating that there is not a pronounced pharmacokinetic interaction between lometrexol and folic acid."	( Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement. Boddy, A; Calvert, AH; Laohavinij, S; Newell, DR; Taylor, GA; Wedge, SR, 1995)
" The pharmacokinetics of the classical antifolate methotrexate have been well-defined and pharmacokinetic data can be exploited to reduce the toxicity and enhance the activity of the drug."	( Clinical pharmacokinetics of antitumor antifolates. Newell, DR, 1999)

Excerpt	Reference
"The presence of low concentrations of the lipophilic dihydrofolate reductase inhibitors metoprine or trimetrexate, which cause little inhibition in the growth of cultured hepatoma cells in combination with weakly inhibiting concentrations of 5,10-dideazatetrahydrofolate, exhibit greater activity than would be predicted by the activity of the individual components."	( Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate. Boschelli, D; Galivan, J; Kerwar, SS; Nimec, Z; Oronsky, AL; Rhee, M, 1988)
" This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation."	( A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Bailey, N; Boddy, AV; Calvert, AH; Chapman, F; Gumbrell, L; Humphreys, A; Laohavinij, S; Lind, MJ; Newell, DR; Oakley, A; Proctor, M; Robson, L; Simmons, D; Taylor, GA; Thomas, HD; Wedge, SR, 1996)
" Lometrexol pharmacokinetics were also examined in seven patients who received 45 or 60 mg/m2 lometrexol as part of a separate study of the drug given with folinic acid rescue 5-7 days after treatment."	( Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement. Boddy, A; Calvert, AH; Laohavinij, S; Newell, DR; Taylor, GA; Wedge, SR, 1995)

Excerpt	Reference
" The results suggest that tumors can compensate for low folate bioavailability by up-regulation of a second FR with slightly lower affinity for folic acid."	( The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. Gates, SB; Grindey, GB; Habeck, LL; Mendelsohn, LG; Shackelford, KA; Shih, C; Worzalla, J, 1996)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)

Excerpt	Reference
" Optimization of the folic acid content in the diet and of the lometrexol dosage are predicted to have substantial impact on the clinical activity of this class of drugs."	( Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Alati, T; Bewley, JR; Grindey, GB; Lewis, S; Moran, RG; Shih, C; Worzalla, JF, 1996)
" Animals were sacrificed both early and late (7 days) after dosing to determine the long-term retention of these compounds."	( Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet. Chay, SH; Habeck, LL; Mendelsohn, LG; Pohland, RC; Shih, C; Worzalla, JF, 1998)
" The every three week dosing schedule has proven to be convenient and easy to administer and the clinical toxicities of LY231514 seem to be well tolerated."	( Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Chen, VJ; Habeck, LL; Mendelsohn, LG; Schultz, RM; Shih, C, 1998)

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Phosphoribosylglycinamide formyltransferase	Escherichia coli K-12	Ki	0.0800	0.0600	0.0800	0.1000	AID1798216
Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)	IC50 (µMol)	2.8508	0.0058	0.3122	3.0000	AID159252; AID349815; AID362438; AID459869; AID695101
Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)	Ki	0.0580	0.0060	0.2592	1.0000	AID1297315; AID1798216; AID1798461; AID264569; AID360484; AID363071
Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)	Ki	100.0000	0.4000	0.6400	0.8800	AID1798460; AID264570; AID363072
Trifunctional purine biosynthetic protein adenosine-3	Mus musculus (house mouse)	IC50 (µMol)	0.7800	0.7800	0.7800	0.7800	AID349814; AID362437; AID459868
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
DNA damage response	Phosphoribosylglycinamide formyltransferase	Escherichia coli K-12
purine nucleotide biosynthetic process	Phosphoribosylglycinamide formyltransferase	Escherichia coli K-12
'de novo' IMP biosynthetic process	Phosphoribosylglycinamide formyltransferase	Escherichia coli K-12
brainstem development	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
GMP biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
'de novo' IMP biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
glycine metabolic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
purine ribonucleoside monophosphate biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
response to organic substance	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
response to inorganic substance	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
cerebellum development	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
cerebral cortex development	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
'de novo' AMP biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
tetrahydrofolate biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
'de novo' XMP biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
purine nucleotide biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
adenine biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
brainstem development	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
nucleobase-containing compound metabolic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
GMP biosynthetic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
'de novo' IMP biosynthetic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
response to inorganic substance	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
cerebellum development	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
cerebral cortex development	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
animal organ regeneration	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
'de novo' AMP biosynthetic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
dihydrofolate metabolic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
tetrahydrofolate biosynthetic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
'de novo' XMP biosynthetic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
cellular response to interleukin-7	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
catalytic activity	Phosphoribosylglycinamide formyltransferase	Escherichia coli K-12
phosphoribosylglycinamide formyltransferase activity	Phosphoribosylglycinamide formyltransferase	Escherichia coli K-12
transferase activity	Phosphoribosylglycinamide formyltransferase	Escherichia coli K-12
phosphoribosylamine-glycine ligase activity	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
phosphoribosylformylglycinamidine cyclo-ligase activity	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
phosphoribosylglycinamide formyltransferase activity	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
ATP binding	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
metal ion binding	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
IMP cyclohydrolase activity	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
protein homodimerization activity	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
cadherin binding	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
phosphoribosylaminoimidazolecarboxamide formyltransferase activity	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	Phosphoribosylglycinamide formyltransferase	Escherichia coli K-12
cytoplasm	Phosphoribosylglycinamide formyltransferase	Escherichia coli K-12
cytosol	Phosphoribosylglycinamide formyltransferase	Escherichia coli K-12
cytosol	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
cytosol	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
extracellular exosome	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
cytosol	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
plasma membrane	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
membrane	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
extracellular exosome	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
cytosol	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (96)

Assay ID	Title	Year	Journal	Article
AID362422	Antiproliferative activity against human RFC expressing Chinese hamster R2 cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID362433	Inhibition of human RFC-mediated [3H]MTX transport in Chinese hamster PC43-10 cells at 10 uM	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID264569	Inhibition of human recombinant GAR Tfase	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.
AID349815	Inhibition of GARFTase in human KB cells assessed as inhibition of incorporation of [14C]glycine into [14C]formyl GAR after 30 mins in presence of azaserine	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transpo
AID362426	Antiproliferative activity against human FRbeta expressing Chinese hamster D4 cells in presence of folic acid	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID264574	Antiproliferative activity against FPGS-deficient CCRF-CEM cell line	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.
AID621126	Antiproliferative activity against chinese hamster D4 cells expressing human FRbeta assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1053447	Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID43706	In vitro antitumor activity was assessed from rate of cell growth of CCRF/CEM cell line	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Thienyl and thiazolyl acyclic analogues of 5-deazatetrahydrofolic acid.
AID459864	Displacement of [3H]folic acid from human FRbeta expressed in Chinese hamster D4 cells relative to unlabeled folic acid	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID264573	Antiproliferative activity against human CCRF-CEM cell line in presence of hypoxanthine	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.
AID264575	Antiproliferative activity against reduced folate carrier-deficient CCRF-CEM cell line	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.
AID362425	Antiproliferative activity against human FRbeta expressing Chinese hamster D4 cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID360482	Inhibition of IMPCH activity of human wild-type ATIC	2007	The Journal of biological chemistry, Apr-27, Volume: 282, Issue:17	Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase.
AID621180	Decrease in intracellular ATP concentration in chinese hamster R2 cells expressing human PCFT at 1 uM after 24 hrs by HPLC relative to control at pH 6.8	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID71493	First order catalytic rate constants (k) was determined from mouse liver Folyl-polyglutamate synthase	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.
AID105287	Ability to inhibit [3H]methotrexate transport into MOLT-4 cells in vitro	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Thienyl and thiazolyl acyclic analogues of 5-deazatetrahydrofolic acid.
AID621181	Inhibition of GARFTase in chinese hamster R2 cells expressing human PCFT assessed as incorporation of [14C]glycine into [14C]formyl GAR in the presence of 4 uM azaserine	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID360483	Inhibition of Escherichia coli GAR transformylase	2007	The Journal of biological chemistry, Apr-27, Volume: 282, Issue:17	Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase.
AID362421	Antiproliferative activity against human RFC expressing Chinese hamster PC43-10 cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID695102	Inhibition of GARFTase in human KB cells assessed as reduction in [14C]glycine incorporation into [14C]formyl GAR incubated for 15 hrs in complete folate free RPMI medium in presence of 2 nM leucovorin	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter
AID1053450	Growth inhibition of Chinese hamster D4 cells after 96 hrs by CellTiter-blue assay in presence of folic acid	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID1053453	Growth inhibition of Chinese hamster RT16 cells after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID362440	Induction of apoptotic activity in human KB cells at 1 uM after 24 hrs	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID264572	Antiproliferative activity against human CCRF-CEM cell line in presence of thymidine	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.
AID621132	Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1053448	Growth inhibition of Chinese hamster R2(VC) cells after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID621136	Inhibition of human RFC-mediated [3H]MTX uptake in chinese hamster PC43-10 cells at 10 uM after 2 mins relative to control	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID18268	Km of Hog folyl-poly-glutamate synthase (FPGS) relative to aminopterin	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Thienyl and thiazolyl acyclic analogues of 5-deazatetrahydrofolic acid.
AID264570	Inhibition of human recombinant AICAR Tfase	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.
AID362437	Inhibition of mouse recombinant GARFTase	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID362424	Antiproliferative activity against human FRalpha expressing Chinese hamster RT16 cells in presence of folic acid	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID363076	Cytotoxicity against folyl-poly-glutamate synthetase-deficient human CCRF-CEM cells in absence of thymidine and hypoxanthine	2008	Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.
AID43686	Cytotoxicity in the absence of thymidine and hypoxanthine against CCRF-CEM cell line	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Design, synthesis, and biological evaluation of fluoronitrophenyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase.
AID1297315	Inhibition of GARFTase (unknown origin)	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID349814	Inhibition of mouse recombinant GARFTase	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transpo
AID621125	Antiproliferative activity against chinese hamster RT16 cells expressing human FRalpha assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1053446	Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID621130	Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID22818	Vmax of Hog folyl-poly-glutamate synthase (FPGS) relative to aminopterin	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Thienyl and thiazolyl acyclic analogues of 5-deazatetrahydrofolic acid.
AID459867	Displacement of [3H]MTX from human RFC expressed in Chinese hamster PC43-10 cells at 10 uM	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID103887	Ability to inhibit growth of MCF-7 human breast adenocarcinoma in vitro	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Thienyl and thiazolyl acyclic analogues of 5-deazatetrahydrofolic acid.
AID1053449	Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID1053454	Growth inhibition of Chinese hamster MTXRII-OuaR2-4 cells after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID71383	Apparent catalytic rate constants (Km) owas determined from mouse liver Folyl-polyglutamate synthase	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.
AID459869	Inhibition of GARFtase in human KB cells assessed as [14C]glycine incorporation in to [14C]FGAR in folate free RPMI medium with 2 nM LCV by in-situassay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID44015	Compound was tested for its antitumor activity against human lymphoblastic leukemic cells(CCRF-CEM) in vitro	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.
AID264571	Antiproliferative activity against human CCRF-CEM cell line	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.
AID1053452	Growth inhibition of Chinese hamster RT16 cells after 96 hrs by CellTiter-blue assay in presence of folic acid	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID363073	Cytotoxicity against human CCRF-CEM cells in absence of thymidine and hypoxanthine	2008	Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.
AID621135	Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as inhibition of colony formation after 10 to 14 days	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID621123	Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID621131	Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID43688	Cytotoxicity in the presence of thymidine and hypoxanthine against CCRF-CEM cell line	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Design, synthesis, and biological evaluation of fluoronitrophenyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase.
AID1631978	Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue fluorescence analysis	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesi
AID360485	Inhibition of human recombinant AICAR transformylase	2007	The Journal of biological chemistry, Apr-27, Volume: 282, Issue:17	Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase.
AID621124	Antiproliferative activity against chinese hamster RT16 cells expressing human FRalpha assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID621133	Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID459868	Inhibition of mouse recombinant GARFtase assessed as FGAR formation by spectrophotometry	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID159252	Ability to inhibit glycinamide ribonucleotide transformylase (GAR-Tfase) in vitro, using hog liver with (6R)-10-formyl-FH4 as cofactor	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Thienyl and thiazolyl acyclic analogues of 5-deazatetrahydrofolic acid.
AID459863	Displacement of [3H]folic acid from human FRalpha expressed in Chinese hamster RT16 cells relative to unlabeled folic acid	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID621127	Antiproliferative activity against chinese hamster D4 cells expressing human FRbeta assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID360484	Inhibition of human recombinant GAR transformylase	2007	The Journal of biological chemistry, Apr-27, Volume: 282, Issue:17	Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase.
AID43685	Cytotoxicity in the absence of hypoxanthine and presence of thymidine against CCRF-CEM cell line	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Design, synthesis, and biological evaluation of fluoronitrophenyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase.
AID363072	Inhibition of human recombinant AICAR transformylase	2008	Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.
AID621128	Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID695101	Inhibition of GARFTase in human IGROV1 cells assessed as reduction in [14C]glycine incorporation into [14C]formyl GAR incubated for 15 hrs in complete folate free RPMI medium in presence of 2 nM leucovorin	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter
AID43705	Cytotoxicity against human lymphoblastic leukemic CCRF-CEM cell line was evaluated as the concentration required for 50% inhibition of the growth of the control value	1992	Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6	Synthesis and biological activity of acyclic analogues of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid.
AID621129	Antiproliferative activity against chinese hamster R2(VC) cells expressing human PCFT assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID362438	Inhibition of GARFTase in human KB cells assessed as inhibition of [14C]glycine incorporation into [14C]formylGAR in presence of azaserine	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1062553	Cytotoxicity against chinese hamster R2(VC) cells after 96 hrs by CellTitre-Blue fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID362429	Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID362430	Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID621122	Antiproliferative activity against chinese hamster PC43-10 expressing human RFC assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID363071	Inhibition of human recombinant GAR transformylase	2008	Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.
AID363074	Cytotoxicity against human CCRF-CEM cells in presence of thymidine and absence of hypoxanthine	2008	Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.
AID1053451	Growth inhibition of Chinese hamster D4 cells after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID363075	Cytotoxicity against human CCRF-CEM cells in absence of thymidine and presence of hypoxanthine	2008	Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.
AID1062554	Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID362423	Antiproliferative activity against human FRalpha expressing Chinese hamster RT16 cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID43687	Cytotoxicity in the absence of thymidine and presence of hypoxanthine against CCRF-CEM cell line	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Design, synthesis, and biological evaluation of fluoronitrophenyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase.
AID363077	Cytotoxicity against human CCRF-CEM cells expressing reduced folate carrier in absence of thymidine and hypoxanthine	2008	Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.
AID1053455	Growth inhibition of Chinese hamster PC43-10 cells after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID362428	Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID71491	Catalytic rate constants (Vmax) was determined from mouse liver Folyl-polyglutamate synthase	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.
AID362427	Antiproliferative activity against human RFC and FRalpha expressing human KB cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1798216	GAR Tfase Activity Assay from Article 10.1074/jbc.M607293200: \\Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase.\\	2007	The Journal of biological chemistry, Apr-27, Volume: 282, Issue:17	Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase.
AID1798461	GAR Tfase Activity Assay from Article 10.1021/jm800555h: \\Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.\\	2008	Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.
AID1798460	AICAR Tfase Inhibition Assay from Article 10.1021/jm800555h: \\Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.\\	2008	Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	11 (9.32)	18.7374
1990's	72 (61.02)	18.2507
2000's	20 (16.95)	29.6817
2010's	11 (9.32)	24.3611
2020's	4 (3.39)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	7 (5.88%)	5.53%
Reviews	9 (7.56%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	103 (86.55%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I Trial of Lometrexol Sodium and Paclitaxel Adminsitered Intravenously Every 21 Days in Conjunction With Oral Folic Acid in Patients With Solid Tumors[NCT00024310]	Phase 1	0 participants	Interventional	2001-09-30	Active, not recruiting
A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer[NCT00033722]	Phase 2	0 participants	Interventional	2002-02-28	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
phosphoribosyl-n-formylglycineamide [no description available]	1.97	1	0
glycine [no description available]	1.97	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
purine 1H-purine : The 1H-tautomer of purine.. 3H-purine : The 3H-tautomer of purine.. 9H-purine : The 9H-tautomer of purine.. 7H-purine : The 7H-tautomer of purine.	3.81	3	0	purine
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	7.4	2	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	2.03	1	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	1.98	1	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.08	1	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
pyrimethamine Maloprim: contains above 2 cpds	2.38	2	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.1	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
trimetrexate Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.	4.98	7	0
thymidine [no description available]	2.67	3	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.	1.98	1	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	1.99	1	0	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
uridine triphosphate Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.	1.97	1	0	pyrimidine ribonucleoside 5'-triphosphate; uridine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	1.99	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
cytidine triphosphate Cytidine Triphosphate: Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety.	1.97	1	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite
ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.	2.01	1	0	non-proteinogenic L-alpha-amino acid; ornithine	algal metabolite; hepatoprotective agent; mouse metabolite
phosphoribosyl pyrophosphate Phosphoribosyl Pyrophosphate: The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides.. 5-phosphoribosyl diphosphate : A ribose diphosphate carrying an additional phosphate group at position 5.. 5-O-phosphono-alpha-D-ribofuranosyl diphosphate : A derivative of alpha-D-ribose having a phosphate group at the 5-position and a diphosphate at the 1-position.	1.98	1	0	5-O-phosphono-D-ribofuranosyl diphosphate	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	3.08	1	0	pyrrole; secondary amine
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	7.39	15	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	7.55	18	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	3.1	1	0	diazine; pyrazines	Daphnia magna metabolite
nitroblue tetrazolium Nitroblue Tetrazolium: Colorless to yellow dye that is reducible to blue or black formazan crystals by certain cells; formerly used to distinguish between nonbacterial and bacterial diseases, the latter causing neutrophils to reduce the dye; used to confirm diagnosis of chronic granulomatous disease.	1.97	1	0	organic cation
aminoimidazole carboxamide Aminoimidazole Carboxamide: An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases.. 5-aminoimidazole-4-carboxamide : An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.	2.41	2	0	aminoimidazole; monocarboxylic acid amide	mouse metabolite
thymidine monophosphate Thymidine Monophosphate: 5-Thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety.. dTMP : The neutral species of thymidine 5'-monophosphate (2'-deoxythymidine 5'-monophosphate).	2.38	2	0	thymidine 5'-monophosphate	fundamental metabolite
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	1.99	1	0	dialdehyde	biomarker
methylnitrosourea Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.	2	1	0	N-nitrosoureas	alkylating agent; carcinogenic agent; mutagen; teratogenic agent
4-vinylbenzoic acid [no description available]	1.99	1	0
2'-deoxyadenosine triphosphate 2'-deoxyadenosine triphosphate: RN given refers to unlabeled parent cpd	1.97	1	0	2'-deoxyadenosine 5'-phosphate; purine 2'-deoxyribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite
metoprine metoprine: histamine methyltransferase antagonist	1.97	1	0
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	2.04	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
piritrexim piritrexim: RN given refers to parent cpd; structure given in first source	4	2	0
thymidine 5'-triphosphate thymidine 5'-triphosphate: RN given refers to parent cpd. dTTP : A thymidine phosphate having a triphosphate group at the 5'-position.	1.97	1	0	pyrimidine 2'-deoxyribonucleoside 5'-triphosphate; thymidine phosphate	Escherichia coli metabolite; mouse metabolite
aica ribonucleotide AICA ribonucleotide: purine precursor that has antineoplastic activity. AICA ribonucleotide : A 1-(phosphoribosyl)imidazolecarboxamide that is acadesine in which the hydroxy group at the 5' position has been converted to its monophosphate derivative.	2.03	1	0	1-(phosphoribosyl)imidazolecarboxamide; aminoimidazole	cardiovascular drug; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
ecteinascidin 743 [no description available]	3.1	1	0	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	3.1	1	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
methotrexate [no description available]	7.88	40	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
talotrexin N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine: RN refers to (S)-isomer	2.73	3	0
10-propargyl-10-deazaaminopterin 10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.	2.08	1	0	N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
glycineamide ribonucleotide glycineamide ribonucleotide: structure	2.4	2	0
5-formamidoimidazole-4-carboxamide ribotide 5-formamidoimidazole-4-carboxamide ribotide: purine precursor	2.03	1	0	1-(phosphoribosyl)imidazolecarboxamide	Escherichia coli metabolite; mouse metabolite
aminopterin Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.	5.2	9	0	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
bortezomib [no description available]	3.1	1	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
5'-methylthioadenosine 5'-methylthioadenosine: structure. 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group.	1.98	1	0	thioadenosine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.03	1	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.03	1	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	3.1	1	0	stilbene
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.57	2	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
fosbretabulin fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source	3.1	1	0
tanespimycin CP 127374: analog of herbimycin A	3.1	1	0	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
edatrexate edatrexate: structure given in first source	4.85	6	0	glutamic acid derivative
ag 331 AG 331: structure given in second source	3.1	1	0
levoleucovorin Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.	5.9	9	3	5-formyltetrahydrofolic acid	antineoplastic agent; metabolite
deoxyguanosine triphosphate [no description available]	1.99	1	0	deoxyguanosine phosphate; guanyl deoxyribonucleotide; purine 2'-deoxyribonucleoside 5'-triphosphate	Arabidopsis thaliana metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.67	3	0	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanine [no description available]	6.47	9	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
hypoxanthine [no description available]	8.68	10	0	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	10.38	38	4	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
raltitrexed [no description available]	7.47	20	0	N-acyl-amino acid
nolatrexed nolatrexed: structure given in first source; RN given refers to dihydrochloride	3.81	3	0
ici 198583 ICI 198583: RN & structure given in first source	2.38	2	0
leucovorin 5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.	2.74	3	0	formyltetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
1843u89 1843U89: structure given in first source; a folate analog	4.29	3	0
5,11-methenyltetrahydrohomofolate [no description available]	2.38	2	0
alanosine [no description available]	1.99	1	0
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	7.14	18	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
n-(4-((3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propyl)amino)benzoyl)glutamic acid N-(4-((3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propyl)amino)benzoyl)glutamic acid: RN & structure given in first source; inhibitor of glycinamide ribonucleotide transformylase and aminoimidazole ribonucleotide transformylase; an anti-purine drug	1.98	1	0
zd 9331 ZD 9331: BGC9331 was formerly known as ZD9331; structure in first source	4.3	3	0
s-adenosylmethionine 5-deazafolic acid: structure given in first source	1.98	1	0
ag 2034 AG 2034: inhibits glycinamide ribonucleotide formyltransferase; structure given in first source	2.41	2	0	glutamic acid derivative
5-methyltetrahydrofolate 5-methyltetrahydrofolate : A group of heterocyclic compounds based on the 5-methyl-5,6,7,8-tetrahydropteroic acid skeleton conjugated with one or more L-glutamic acid or L-glutamate units.	2.39	2	0
2-desamino-2-methyl-5,8-dideazaisofolic acid 2-desamino-2-methyl-5,8-dideazaisofolic acid: structure given in first source	2	1	0
5-deaza-5,6,7,8-tetrahydrofolic acid 5-deaza-5,6,7,8-tetrahydrofolic acid: RN given refers to (6R)-isomer; RN for cpd without isomeric designation not available 8/89; RN & structure given in first source	2.68	3	0

Condition	Indicated	Relationship Strength	Studies	Trials
Adenocarcinoma, Basal Cell [description not available]	0	3.59	3	0
Leukemia, Lymphocytic [description not available]	0	3.23	6	0
Experimental Mammary Neoplasms [description not available]	0	3.59	3	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	3.59	3	0
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	0	3.23	6	0
Leukemia L 1210 [description not available]	0	5.14	18	0
Breast Cancer [description not available]	0	2.39	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.39	2	0
Acute Lymphoid Leukemia [description not available]	0	2.92	4	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	0	2.92	4	0
Benign Neoplasms [description not available]	0	7.94	11	5
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	9.94	11	5
Carcinoma, Epidermoid [description not available]	0	2.41	2	0
Cancer of Ovary [description not available]	0	2.91	4	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	2.41	2	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.91	4	0
Plasmodium falciparum Malaria [description not available]	0	2.1	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	0	2.1	1	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
African Lymphoma [description not available]	0	2.25	1	0
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	0	2.25	1	0
Recrudescence [description not available]	0	2.11	1	0
B-Cell Leukemia [description not available]	0	2.11	1	0
Cancer of Colon [description not available]	0	2.68	3	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	2.68	3	0
Acute Myelogenous Leukemia [description not available]	0	2.03	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	2.03	1	0
Cancer of Nasopharynx [description not available]	0	1.98	1	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	0	1.98	1	0
Leucocythaemia [description not available]	0	3.24	6	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	3.24	6	0
Experimental Hepatoma [description not available]	0	2.67	3	0
Deficiency, Folic Acid [description not available]	0	2.39	2	0
Folic Acid Deficiency A nutritional condition produced by a deficiency of FOLIC ACID in the diet. Many plant and animal tissues contain folic acid, abundant in green leafy vegetables, yeast, liver, and mushrooms but destroyed by long-term cooking. Alcohol interferes with its intermediate metabolism and absorption. Folic acid deficiency may develop in long-term anticonvulsant therapy or with use of oral contraceptives. This deficiency causes anemia, macrocytic anemia, and megaloblastic anemia. It is indistinguishable from vitamin B 12 deficiency in peripheral blood and bone marrow findings, but the neurologic lesions seen in B 12 deficiency do not occur. (Merck Manual, 16th ed)	0	2.39	2	0
Acute Promyelocytic Leukemia [description not available]	0	2.67	3	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	0	2.67	3	0
Experimental Neoplasms [description not available]	0	2.39	2	0
Di Guglielmo Disease [description not available]	0	1.98	1	0
Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.	0	1.98	1	0
Blood Diseases [description not available]	0	3.37	1	1
Hematologic Diseases Disorders of the blood and blood forming tissues.	0	3.37	1	1
Carcinoma, Non-Small Cell Lung [description not available]	0	1.98	1	0
Cancer of Lung [description not available]	0	2.39	2	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	1.98	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	1	4.39	2	0
Pancytopenia Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.	0	3.37	1	1
Mucositis, Oral [description not available]	0	3.37	1	1
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	0	3.37	1	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.4	2	0
Bone Marrow Diseases Diseases involving the BONE MARROW.	0	3.37	1	1
Cholera Infantum [description not available]	0	3.37	1	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	0	3.37	1	1
Sarcoma, Epithelioid [description not available]	0	1.98	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	1.98	1	0
Adjuvant Arthritis [description not available]	0	2	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	0	2	1	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	0	2	1	0
Germinoblastoma [description not available]	0	3.78	2	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	3.39	1	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	0	3.78	2	1
Cancer of Head [description not available]	0	1.98	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	0	1.98	1	0
ATLL [description not available]	0	1.97	1	0
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	0	1.97	1	0

lometrexol

Description

Cross-References

Synonyms (42)

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (4)

Inhibition Measurements

Biological Processes (19)

Molecular Functions (11)

Ceullar Components (5)

Bioassays (96)

Research

Studies (118)

Study Types

Clinical Trials (2)

Trial Overview

lometrexol

Description

Cross-References

Synonyms (42)

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (4)

Inhibition Measurements

Biological Processes (19)

Molecular Functions (11)

Ceullar Components (5)

Bioassays (96)

Research

Studies (118)

Study Types

Clinical Trials (2)

Trial Overview

Related Drugs (73)

Related Conditions (66)